amrubicin
3 abstracts
Abstract
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,
Abstract
A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.Org: Department of Thoracic oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Department of Allergy and Respiratory Medicine (Thoracic Oncology), Okayama University Hospital, Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan,
Abstract
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).Org: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom, Fox Chase Cancer Center, Philadelphia, PA,